Dotinurad Treatment for Patients With Hyperuricemia Complicating CKD
Dotinurad therapy may be well-tolerated in patients with hyperuricemia and may have efficacy comparable with existing standard treatment in patients with CKD stages G3/G4. Randomized controlled trials in larger patient groups are needed.
Authors
- Naoki Itabashi (ORCID: https://orcid.org/0009-0006-6013-8687)
- Yasuhiro Onishi (ORCID: https://orcid.org/0000-0002-1544-6270)
- Tomokazu Nunoue
- Akihiro Katayama (ORCID: https://orcid.org/0000-0002-9729-7343)
- Katsuyuki Tanabe (ORCID: https://orcid.org/0000-0003-4767-5892)
- Jun Wada
- Kyoko Watanabe
- Akihiko Nakamura (ORCID: https://orcid.org/0000-0002-7247-8471)
- Shinichi Okada
- Keisuke Maruyama (ORCID: https://orcid.org/0000-0001-5590-4216)
- Hiroyuki Ohbayashi
- Takeshi Hosoya
Institutions
- Okayama University (JP)
- Diabetes Australia (AU)
- Inoue Hospital (JP)
- Okayama Psychiatric Medical Center (JP)
- Okayama Red Cross General Hospital (JP)
- Okayama Saiseikai General Hospital (JP)
- Okayama Medical Center (JP)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1016/j.ekir.2025.03.047
- Citations
- 6
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 8.58